CA3171185A1 - Macrocyclic ulk1/2 inhibitors - Google Patents
Macrocyclic ulk1/2 inhibitorsInfo
- Publication number
- CA3171185A1 CA3171185A1 CA3171185A CA3171185A CA3171185A1 CA 3171185 A1 CA3171185 A1 CA 3171185A1 CA 3171185 A CA3171185 A CA 3171185A CA 3171185 A CA3171185 A CA 3171185A CA 3171185 A1 CA3171185 A1 CA 3171185A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- cycloalkyl
- heterocycloalkyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062977039P | 2020-02-14 | 2020-02-14 | |
| US62/977,039 | 2020-02-14 | ||
| PCT/US2021/018038 WO2021163627A1 (en) | 2020-02-14 | 2021-02-12 | Macrocyclic ulk1/2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3171185A1 true CA3171185A1 (en) | 2021-08-19 |
Family
ID=77292762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3171185A Pending CA3171185A1 (en) | 2020-02-14 | 2021-02-12 | Macrocyclic ulk1/2 inhibitors |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12594277B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4103183A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023513793A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220153582A (cg-RX-API-DMAC10.html) |
| CN (1) | CN115515588A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021221162A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3171185A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021163627A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021216440A1 (en) * | 2020-04-20 | 2021-10-28 | Tenova Pharmaceuticals Inc. | Novel protein kinase inhibitors |
| US20230332243A1 (en) * | 2020-09-30 | 2023-10-19 | Salk Institute For Biological Studies | Patient selection biomarkers for treatment with ulk inhibitors |
| WO2024017251A1 (zh) * | 2022-07-18 | 2024-01-25 | 江苏恒瑞医药股份有限公司 | 抑制并诱导egfr降解的大环类化合物、其制备方法及其在医药上的应用 |
| WO2024017258A1 (zh) * | 2022-07-19 | 2024-01-25 | 百极弘烨(南通)医药科技有限公司 | Egfr小分子抑制剂、含其的药物组合物及其用途 |
| WO2024233766A1 (en) * | 2023-05-10 | 2024-11-14 | Erasca, Inc. | Macrocyclic ulk1/2 inhibitors and their use thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| CA1256638A (en) | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| ES2325440T3 (es) | 2003-02-20 | 2009-09-04 | Smithkline Beecham Corporation | Compuestos de pirimidina. |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| WO2005049021A1 (en) | 2003-11-03 | 2005-06-02 | Oy Helsinki Transplantation R & D Ltd | Materials and methods for inhibiting neointimal hyperplasia |
| EP1758887A1 (en) | 2004-05-14 | 2007-03-07 | Pfizer Products Incorporated | Pyrimidine derivatives for the treatment of abnormal cell growth |
| US20060069110A1 (en) | 2004-09-27 | 2006-03-30 | Andersen Denise L | Substituted heterocyclic compounds and methods of use |
| MY169441A (en) * | 2004-12-08 | 2019-04-11 | Janssen Pharmaceutica Nv | 2,4, (4,6) pyrimidine derivatives |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| WO2006129100A1 (en) | 2005-06-03 | 2006-12-07 | Glaxo Group Limited | Novel compounds |
| WO2007028445A1 (en) | 2005-07-15 | 2007-03-15 | Glaxo Group Limited | 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives |
| DK2089369T3 (da) | 2006-10-19 | 2011-05-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme |
| DE102007010801A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Diaminopyrimidine als Fungizide |
| US20100130496A1 (en) | 2007-04-12 | 2010-05-27 | F. Hoffmann-La Roche Ag | Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase |
| WO2008140421A2 (en) * | 2007-05-15 | 2008-11-20 | S*Bio Pte Ltd | Heterocycloalkyl substituted pyrimidine derivatives |
| US8461147B2 (en) | 2007-12-03 | 2013-06-11 | Boehringer Ingelheim International Gmbh | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| WO2009083185A2 (en) | 2007-12-28 | 2009-07-09 | Fovea Pharmaceuticals Sa | Compositions and methods for prophylaxis and treatment of cellular degenerative ophthalmic disorders |
| CA2723205C (en) | 2008-04-16 | 2017-03-14 | Portola Pharmaceuticals, Inc. | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors |
| CA2722326A1 (en) * | 2008-04-24 | 2009-10-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| WO2009158431A2 (en) | 2008-06-25 | 2009-12-30 | Irm Llc | Compounds and compositions as kinase inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| CA2729121C (en) * | 2008-06-30 | 2019-04-09 | Centocor Ortho Biotech Inc. | Differentiation of pluripotent stem cells |
| US20120114637A1 (en) | 2009-05-04 | 2012-05-10 | Santen Pharmaceutical Co., Ltd. | Mtor pathway inhibitors for treating ocular disorders |
| WO2010146132A1 (en) | 2009-06-18 | 2010-12-23 | Cellzome Limited | Sulfonamides and sulfamides as zap-70 inhibitors |
| WO2011084523A2 (en) | 2009-12-15 | 2011-07-14 | The Salk Institute For Biological Studies | Ulk1 compositions, inhibitors, screening and methods of use |
| SG10201500124VA (en) | 2010-01-08 | 2015-03-30 | Agency Science Tech & Res | Methods and Compositions for Treating Cancer |
| WO2011133668A2 (en) | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
| PT2591006T (pt) | 2010-07-09 | 2019-07-29 | Bioverativ Therapeutics Inc | Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas |
| US20130252950A1 (en) | 2010-09-23 | 2013-09-26 | President And Fellows Of Harvard College | Targeting mtor substrates in treating proliferative diseases |
| WO2012045195A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
| US8691777B2 (en) | 2011-01-27 | 2014-04-08 | Emory University | Combination therapy |
| US20120244209A1 (en) | 2011-03-02 | 2012-09-27 | Roth Jack A | Tusc2 therapies |
| KR20130131461A (ko) | 2011-03-07 | 2013-12-03 | 폰다지오네 텔레톤 | Tfeb 변종 및 그의 용도 |
| US20140343128A1 (en) | 2011-11-15 | 2014-11-20 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the Janus Kinase 2 - Signal Transducer and Activator of Transcription 5 pathway |
| US9073944B2 (en) | 2012-02-21 | 2015-07-07 | Merck Patent Gmbh | Cyclic diaminopyrimidine derivatives |
| US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| WO2014062621A1 (en) | 2012-10-15 | 2014-04-24 | Stc.Unm | Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits |
| RU2702908C2 (ru) | 2012-11-01 | 2019-10-14 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| US20150328193A1 (en) | 2012-12-17 | 2015-11-19 | The Brigham And Women's Hospital, Inc. | Treatment of mtor hyperactive related diseases and disorders |
| CN103059030B (zh) | 2012-12-28 | 2015-04-29 | 北京师范大学 | 一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用 |
| HK1218249A1 (zh) | 2013-01-25 | 2017-02-10 | Rigel Pharmaceuticals, Inc. | 用於治疗炎症性肠道疾病的化合物和方法 |
| BR112015030518A2 (pt) | 2013-06-05 | 2017-08-29 | Salk Inst For Biological Studi | Composição farmacêutica, uso de um ou mais agonistas do receptor da vitamina d (vdr), e, método para a redução da atividade biológica do ligante 12 do motivo c-x-c (cxcl12) |
| CN106536503B (zh) | 2014-04-18 | 2019-09-06 | 北京澳合药物研究院有限公司 | 一种酪氨酸激酶抑制剂及其用途 |
| US10053458B2 (en) | 2014-06-17 | 2018-08-21 | Korea Research Institute Of Chemical Technology | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient |
| ES2914099T3 (es) | 2014-08-25 | 2022-06-07 | Salk Inst For Biological Studi | Inhibidores novedosos de ULK1 y métodos de uso de los mismos |
| RS62017B1 (sr) | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitori i njihova upotreba |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| CN105524045B (zh) | 2014-10-22 | 2020-04-10 | 山东轩竹医药科技有限公司 | 四环类间变性淋巴瘤激酶抑制剂 |
| WO2016090079A1 (en) | 2014-12-05 | 2016-06-09 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| CN106188029B (zh) | 2015-05-05 | 2018-09-18 | 山东轩竹医药科技有限公司 | 二并环类间变性淋巴瘤激酶抑制剂 |
| WO2016196393A2 (en) | 2015-05-29 | 2016-12-08 | Presage Biosciences, Inc. | Autophagy-inhibiting compounds and uses thereof |
| US20170038387A1 (en) | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| CN105801603B (zh) | 2016-04-13 | 2018-10-02 | 成都倍特药业有限公司 | 一种具有大环结构的alk抑制剂及其制备方法 |
| CA3040173A1 (en) | 2016-10-18 | 2018-04-26 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders |
| US11180482B2 (en) | 2016-11-30 | 2021-11-23 | Ariad Pharmaceuticals, Inc. | Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors |
| JP6684700B2 (ja) | 2016-12-26 | 2020-04-22 | アイシン精機株式会社 | 乗員検知装置 |
| EP3620457A4 (en) | 2017-05-02 | 2021-01-06 | Korea Research Institute of Chemical Technology | PYRIMIDE-DERIVATIVE COMPOUND, OPTICAL ISOMER THEREOF, OR PHARMACEUTICAL SALT THEREOF AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF TYRO-3 RELATED DISEASES THEREOF AS ACTIVE SUBSTANCE |
| HUE065486T2 (hu) | 2019-05-10 | 2024-05-28 | Deciphera Pharmaceuticals Llc | Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai |
| HRP20231310T1 (hr) | 2019-05-10 | 2024-02-02 | Deciphera Pharmaceuticals, Llc | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene |
| ES3072710T3 (en) | 2019-06-17 | 2026-07-03 | Deciphera Pharmaceuticals Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
| CA3171187A1 (en) | 2020-02-14 | 2021-08-19 | Salk Institute For Biological Studies | Inhibitors of ulk1/2 and methods of using same |
| WO2021163633A1 (en) | 2020-02-14 | 2021-08-19 | Salk Institute For Biological Studies | Mono and combination therapies with ulk1/2 inhibitors |
| WO2021216440A1 (en) | 2020-04-20 | 2021-10-28 | Tenova Pharmaceuticals Inc. | Novel protein kinase inhibitors |
| US20230332243A1 (en) | 2020-09-30 | 2023-10-19 | Salk Institute For Biological Studies | Patient selection biomarkers for treatment with ulk inhibitors |
-
2021
- 2021-02-12 US US17/799,634 patent/US12594277B2/en active Active
- 2021-02-12 EP EP21753844.6A patent/EP4103183A4/en active Pending
- 2021-02-12 CA CA3171185A patent/CA3171185A1/en active Pending
- 2021-02-12 WO PCT/US2021/018038 patent/WO2021163627A1/en not_active Ceased
- 2021-02-12 CN CN202180027809.1A patent/CN115515588A/zh active Pending
- 2021-02-12 JP JP2022549144A patent/JP2023513793A/ja active Pending
- 2021-02-12 AU AU2021221162A patent/AU2021221162A1/en active Pending
- 2021-02-12 KR KR1020227028938A patent/KR20220153582A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230099804A1 (en) | 2023-03-30 |
| US12594277B2 (en) | 2026-04-07 |
| EP4103183A1 (en) | 2022-12-21 |
| AU2021221162A1 (en) | 2022-09-22 |
| JP2023513793A (ja) | 2023-04-03 |
| CN115515588A (zh) | 2022-12-23 |
| KR20220153582A (ko) | 2022-11-18 |
| EP4103183A4 (en) | 2024-02-28 |
| WO2021163627A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12594277B2 (en) | Macrocyclic ULK1/2 inhibitors | |
| CN114929704A (zh) | 含螺环的喹唑啉化合物 | |
| AU2016312011A1 (en) | Process for preparing Parp inhibitor, crystalline forms, and uses thereof | |
| AU2015266453C1 (en) | Alk kinase inhibitor, and preparation method and use thereof | |
| WO2021163629A1 (en) | Inhibitors of ulk1/2 and methods of using same | |
| CN105517549B (zh) | CaMKII抑制剂和其用途 | |
| JP2022521537A (ja) | イミダゾピリジニル化合物及び増殖性障害の処置のためのその使用 | |
| JPWO2020032105A1 (ja) | 光学活性な架橋型ピペリジン誘導体 | |
| EP3496724B1 (en) | Protein kinase regulators | |
| CA3116931A1 (en) | Heterocyclic compounds as bet inhibitors | |
| AU2014230125A1 (en) | Macrocyclic salt-inducible kinase inhibitors | |
| RU2691401C2 (ru) | Подготовка и использование ингибитора киназы | |
| AU2011221849A1 (en) | Pyrazolopyrimidine derivative | |
| EP3452465A1 (en) | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | |
| BR112018072039B1 (pt) | Composto, medicamento, e, uso do composto ou sal do mesmo | |
| KR20200014350A (ko) | 단백질 키나아제 억제제로서의 아미노티아졸 화합물 | |
| AU2009284086B2 (en) | New (poly)aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents | |
| AU2020270908B2 (en) | Degradation of AKT by conjugation of ATP-competitive AKT inhibitor GDC-0068 with E3 ligase ligands and methods of use | |
| KR20240041340A (ko) | 피롤로피리미딘 유도체 화합물 및 이의 용도 | |
| WO2022248682A1 (en) | Compounds for degradation of cyclin-dependent kinase 7 (cdk7) | |
| RU2851633C1 (ru) | Соединения хиназолина, содержащие спиро-кольцо | |
| CN102911197B (zh) | 喜树碱硅杂衍生物、含该衍生物的组合物及其用途 | |
| CN116693515A (zh) | 一种gst蛋白抑制剂、其制备方法、药用组合物及其用途 | |
| HK40078982B (en) | Trka inhibitor | |
| EA051813B1 (ru) | Пиразолопиримидиновое соединение, его фармацевтическая композиция, способ лечения и применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220908 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240823 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241105 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250130 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250527 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250527 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250605 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250909 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251021 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251022 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251029 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20260218 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260326 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20260429 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260429 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260806 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260806 |